o2h Ventures

🧑🔬“The UK  punches well above its weight, bringing in over 40% of all biotech investments across Europe as geography.  Despite these facts, there is a significant and well-understood valuation gap between the UK and other regions…” - Sunil Shah What is happening within the UK biotech sector? Explore:  - The truth about the UK biotech landscape - Sunil Shah’s journey from consultant to biotech leader - The valuation gap impacting the sector and more... 🔗 Click here to read the full article by the Life Science Nation - https://lnkd.in/g_8Jnvvi #o2h #seedingnewideas #biotech #lifescience #o2hVentures

We are pleased to announce that Sunil Shah, Managing Partner at o2hVentures, is taking the stage alongside other esteemed panellists at #RESI Boston to discuss "𝗙𝗮𝗺𝗶𝗹𝘆 𝗢𝗳𝗳𝗶𝗰𝗲𝘀: 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀 𝗼𝗻 𝗘𝗮𝗿𝗹𝘆 𝗦𝘁𝗮𝗴𝗲 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁𝘀."   Join us at this prestigious #RESIBoston24 Conference, organized by Life Science Nation, to explore the latest trends and opportunities in life science investing. We are eager to connect with fellow investors and stakeholders from around the globe.   #o2hVentures #biotech #lifescience #investment

🧬🚴♀️𝖦𝖾𝖺𝗋 𝗎𝗉 𝖿𝗈𝗋 𝖺𝗇𝗈𝗍𝗁𝖾𝗋 #𝖢𝖺𝗆𝖻𝗋𝗂𝖽𝗀𝖾 𝖡𝗂𝗈𝗍𝖾𝖼𝗁 𝖡𝗂𝗄𝖾𝗋𝗌 𝖾𝗏𝖾𝗇𝗍!   Kicking off the Profile 2024 series, BiotechBikers are zooming into Cambridge on 7th September 2024!    Join us for another exhilarating ride with fellow biotech enthusiasts on a crisp Saturday morning! The format remains familiar, but the excitement is always fresh.   The day will kick off at 08:30 with a quick breakfast, featuring an insightful talk by Shasheen Payoe, PhD from Miltenyi Biotec. Following this, there will be plenty of time to engage in conversations. Riders can then choose between two scenic routes, approximately 65km or 35km, catering to all experience levels. We'll wrap up with a delicious lunch buffet at our Headquarters, Hauxton House.   Whether you're a seasoned participant or new to BiotechBikers, we can't wait to ride with you!   👉 Register Now: https://lnkd.in/dkn7S2TF #o2hVentures #biotech #seedingnewideas o2h group

We are excited to share that Sunil Shah, CEO of o2h Ventures, will be speaking at the 30th anniversary event hosted by the Enterprise Investment Scheme Association (EISA) on 18th September in London. Sunil will be part of a panel discussion on "Unlocking Scientific Breakthroughs with EIS," exploring how these schemes can drive innovation and growth in the scientific community. #o2hVentures #eis #seis #UK #startup

We at o2h Ventures are looking for someone who knows the ins and outs of the UK's highly beneficial #EIS and #SEIS schemes—someone who is excited about educating others on the benefits of these schemes, empowering them, and building relationships in the industry.     We are passionate about investing in early-stage biotech companies and are building a biotech ecosystem here in Cambridge, UK. So far, we have invested in 35 of the UK’s biotech companies; several of these have moved on further to raise significant capital from overseas and are building life-saving drugs/techs to benefit human health.   📌Apply here: https://lnkd.in/d8tDAujq or email us at [email protected]    Know someone perfect for this role? Mention or share with them in the comments!   #o2hVentures #UK #hiring #taxefficientfund #biotech

Check out some key figures for biotech financing in the latest report published by the BioIndustry Association (BIA): 🚀A remarkable 𝟭𝟯𝟱% 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 in funding from Q1 2024 📈The 𝗵𝗶𝗴𝗵𝗲𝘀𝘁-𝗲𝘃𝗲𝗿 quarterly raise since 2021 💡𝗥𝗶𝘀𝗲 in early-stage biotech deals: 15 in Q2 alone, compared to 28 in all of 2023 These figures highlight growing confidence among global investors and a well-positioned pipeline for the UK biotech sector. Explore more insights and detailed figures, here: https://lnkd.in/e94GgQWd #o2hVentures #UK #biotech #investment

🎉 Thrilled to share that o2h Ventures has once again been named a Finalist in the 𝗕𝗲𝘀𝘁 𝗘𝗜𝗦 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 - 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 Category at the Growth Investor Awards 2024! This marks our third consecutive year qualifying for this prestigious award, and after being honoured as the runner-up last year, we are more driven than ever to continue our mission. As a leading biotech specialist tax-efficient fund manager, we are deeply committed to fostering innovation and supporting early-stage biotech companies across the #UK. 👏 Huge congratulations to all the incredible finalists! Check out the full list here: https://lnkd.in/d-gNCXH3  #o2hVentures #biotech #eis #seis #awards

🎉 We are glad to announce our partnership for the 30th Anniversary EIS Celebration by the Enterprise Investment Scheme Association (EISA). The event celebrates three decades of the UK’s most innovative tax-efficient schemes, which aim to provide finance and nurture early-stage companies while providing attractive tax benefits to investors. We look forward to the 18th of September to hear exciting panel discussions, network with our peers, and connect with founders, fund managers, investors, and the wider EIS/SEIS ecosystem. 👉 Click here to learn more about the event, and get your ticket now: https://lnkd.in/db9Mnve6 #o2hVentures #uk #eis #seis #network #events

Great to be a Podium Partner and looking forward to more collaborative rides in #Cambridge. #o2hVentures #seedingnewideas #biotechbikers #biotech

𝗠𝗮𝗿𝗸𝗶𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗠𝗼𝗻𝘁𝗵 𝘄𝗶𝘁𝗵 BiVictriX Therapeutics plc! June is Cancer Immunotherapy Month, and we are thrilled to highlight one of our portfolio companies, BiVictriX Therapeutics (AIM: BVX), working towards developing safer and more effective treatments for #cancer therapies. Here are some of the key milestones they achieved this month! ✔ ️Secured £370K non-dilutive funding from Innovate UK to accelerate the development of their second therapeutic programme, BVX002, which targets ovarian cancer treatment.  ✔Their lead candidate, BVX001, aimed at treating Acute Myeloid Leukemia (AML), demonstrated a compelling safety profile in pre-clinical models. The toxicity results were favourable compared to FDA-approved Antibody Drug Candidates (ADCs), supporting progression to IND-enabling studies. To learn more about the exciting work they are doing, please visit - https://bivictrix.com #o2hVentures #eis #seis #portfolio #news #portfolionews